

Ostomy Care Continence Care Wound & Skin Care Interventional Urology

# Coloplast – transactions in connection with share buy-back programme, week 14

As mentioned in Announcement no. 03/2022 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.

The programme commenced on 21 February 2022 and will end no later than 19 August 2022.

The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.0

The following transactions have been executed during the period 4 – 8 April 2022:

Date	Number of shares	Average purchase price, DKK	Transaction value, DKK
4 April 2022	-	-	-
5 April 2022	-	-	-
6 April 2022	-	-	-
7 April 2022	-	-	-
8 April 2022	27,398	1,070.09	29,318,460
Accumulated until now under the programme	420,686	955.57	401,994,106

Henceforth, Coloplast owns 3,600,802 treasury B shares of DKK 1 equal to 1.67% of the company's total share capital.

An overview showing the transaction data for the period 4 – 8 April 2022 is enclosed.

Kind regards, Investor Relations Coloplast A/S Tel. +45 4911 1800 Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Tel: +45 4911 1111 www.coloplast.com Company reg. (CVR) no. 69749917



Ostomy Care Continence Care Wound & Skin Care Interventional Urology

#### **Our mission**

Making life easier for people with intimate healthcare needs

## Our values

Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us

## Our vision

Setting the global standard for listening and responding

# For further information, please contact

## Investors and analysts

Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111

Ellen Bjurgert Vice President, Investor Relations Tel. +45 4911 1800 /+45 4911 3376 Email: dkebj@coloplast.com

Aleksandra Dimovska Sr. Manager, Investor Relations Tel. +45 4911 1800 /+45 4911 2458 Email: dkadim@coloplast.com

## Press and the media

Peter Mønster Sr. Media Relations Manager Tel. +45 4911 2623 Email: dkpete@coloplast.com

## Address

Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Company reg. (CVR) no. 69749917

# Website

www.coloplast.com

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound & Skin Care, Interventional Urology and Voice & Respiratory Care. We operate globally and employ about 14,000 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2022-04. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Investor Relations Tel. +45 4911 1800 Fax +45 4911 1555 www.coloplast.com Comp. reg. (CVR). 69749917